{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:05:18Z","timestamp":1793822718607,"version":"4.6.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005224","name":"German Center for Neurodegenerative Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005224","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 409\/193-1 FUGG"],"award-info":[{"award-number":["INST 409\/193-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Alzheimer\u2019s disease (AD), fibrillar tau initially occurs locally and progresses preferentially between closely connected regions. However, the underlying sources of regional vulnerability to tau pathology remain unclear. Previous brain-autopsy findings suggest that the myelin levels\u2014which differ substantially between white matter tracts in the brain\u2014are a key modulating factor of region-specific susceptibility to tau deposition. Here, we investigated whether myelination differences between fiber tracts of the human connectome are predictive of the interregional spreading of tau pathology in AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included two independently recruited samples consisting of amyloid-PET-positive asymptomatic and symptomatic elderly individuals, in whom tau-PET was obtained at baseline (ADNI:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009275; BioFINDER-1:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009102) and longitudinally in a subset (ADNI:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009123, mean FU\u2009=\u20091.53 [0.69\u20133.95] years; BioFINDER-1:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939, mean FU\u2009=\u20091.87 [1.21\u20132.78] years). We constructed MRI templates of the myelin water fraction (MWF) in 200\u00a0gray matter ROIs and connecting fiber tracts obtained from adult cognitively normal participants. Using the same 200 ROI brain-parcellation atlas, we obtained tau-PET ROI values from each individual in ADNI and BioFINDER-1. In\u00a0a spatial regression analysis, we first tested the association between cortical myelin and group-average tau-PET signal in the amyloid-positive and control groups. Secondly, employing a previously established approach of modeling tau-PET spreading based on functional connectivity between ROIs, we estimated in\u00a0a linear regression analysis, whether the level of fiber-tract myelin modulates the association between functional connectivity and longitudinal tau-PET spreading (i.e., covariance) between ROIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that higher myelinated cortical regions show lower tau-PET uptake (ADNI: rho\u2009=\u2009\u2009\u2212\u20090.267,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; BioFINDER-1: rho\u2009=\u2009\u2009\u2212\u20090.175,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013). Fiber-tract myelin levels modulated the association between functional connectivity and tau-PET spreading, such that at higher levels of fiber-tract myelin, the association between stronger connectivity and higher covariance of tau-PET between the connected ROIs was attenuated (interaction fiber-tract myelin\u2009\u00d7\u2009functional connectivity: ADNI:\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u2009\u2212\u20090.185,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; BioFINDER-1:\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u2009\u2212\u20090.166,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher levels of myelin are associated with lower susceptibility of the connected regions to accumulate fibrillar tau. These results enhance our understanding of brain substrates that explain regional variation in tau accumulation and encourage future studies to investigate potential underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-01074-9","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T07:03:10Z","timestamp":1664002990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Anna","family":"Rubinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Franzmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dewenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dichgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"issue":"1","key":"1074_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","volume":"13","author":"D Biel","year":"2021","unstructured":"Biel D, Brendel M, Rubinski A, Buerger K, Janowitz D, Dichgans M, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther. 2021;13(1):137.","journal-title":"Alzheimers Res Ther"},{"issue":"524","key":"1074_CR2","doi-asserted-by":"publisher","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1074_CR3","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601\u201312.","journal-title":"Neurology"},{"issue":"3","key":"1074_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271\u20138 (discussion 8-84).","journal-title":"Neurobiol Aging"},{"issue":"4","key":"1074_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1074_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971\u201382.","journal-title":"Neuron"},{"issue":"1","key":"1074_CR7","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun. 2020;11(1):2612.","journal-title":"Nat Commun"},{"issue":"6","key":"1074_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia. Brain. 2019;142(6):1723\u201335.","journal-title":"Brain"},{"issue":"1","key":"1074_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41467-019-14159-1","volume":"11","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer\u2019s disease. Nat Commun. 2020;11(1):347.","journal-title":"Nat Commun"},{"issue":"5","key":"1074_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018;141(5):1517\u201328.","journal-title":"Brain"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"101848","DOI":"10.1016\/j.nicl.2019.101848","volume":"23","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Iaccarino L, Schonhaut DR, Brown JA, La Joie R, O\u2019Neil JP, et al. Tau covariance patterns in Alzheimer\u2019s disease patients match intrinsic connectivity networks in the healthy brain. Neuroimage Clin. 2019;23:101848.","journal-title":"Neuroimage Clin"},{"issue":"48","key":"1074_CR12","doi-asserted-by":"publisher","first-page":"eabd1327","DOI":"10.1126\/sciadv.abd1327","volume":"6","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N, Dewenter A, Frontzkowski L, Dichgans M, Rubinski A, Neitzel J, et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer\u2019s disease. Sci Adv. 2020;6(48):eabd1327.","journal-title":"Sci Adv"},{"issue":"1","key":"1074_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"R van der Kant","year":"2020","unstructured":"van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21(1):21\u201335.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"1074_CR14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/glia.23614","volume":"67","author":"S Timmler","year":"2019","unstructured":"Timmler S, Simons M. Grey matter myelination. Glia. 2019;67(11):2063\u201370.","journal-title":"Glia"},{"issue":"47","key":"1074_CR15","doi-asserted-by":"publisher","first-page":"18618","DOI":"10.1523\/JNEUROSCI.2811-13.2013","volume":"33","author":"H Grydeland","year":"2013","unstructured":"Grydeland H, Walhovd KB, Tamnes CK, Westlye LT, Fjell AM. Intracortical myelin links with performance variability across the human lifespan: results from T1- and T2-weighted MRI myelin mapping and diffusion tensor imaging. J Neurosci. 2013;33(47):18618\u201330.","journal-title":"J Neurosci"},{"key":"1074_CR16","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1038\/ncomms5932","volume":"5","author":"JD Yeatman","year":"2014","unstructured":"Yeatman JD, Wandell BA, Mezer AA. Lifespan maturation and degeneration of human brain white matter. Nat Commun. 2014;5:4932.","journal-title":"Nat Commun"},{"issue":"3","key":"1074_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.neuroimage.2012.07.037","volume":"63","author":"SC Deoni","year":"2012","unstructured":"Deoni SC, Dean DC 3rd, O\u2019Muircheartaigh J, Dirks H, Jerskey BA. Investigating white matter development in infancy and early childhood using myelin water faction and relaxation time mapping. Neuroimage. 2012;63(3):1038\u201353.","journal-title":"Neuroimage"},{"key":"1074_CR18","doi-asserted-by":"publisher","first-page":"117678","DOI":"10.1016\/j.neuroimage.2020.117678","volume":"227","author":"NM Corrigan","year":"2021","unstructured":"Corrigan NM, Yarnykh VL, Hippe DS, Owen JP, Huber E, Zhao TC, et al. Myelin development in cerebral gray and white matter during adolescence and late childhood. Neuroimage. 2021;227:117678.","journal-title":"Neuroimage"},{"issue":"1","key":"1074_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuroimage.2008.11.027","volume":"45","author":"NH Stricker","year":"2009","unstructured":"Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, Haaland KY, et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer\u2019s disease supports retrogenesis. Neuroimage. 2009;45(1):10\u20136.","journal-title":"Neuroimage"},{"issue":"1","key":"1074_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neurobiolaging.2003.03.001","volume":"25","author":"G Bartzokis","year":"2004","unstructured":"Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer\u2019s disease. Neurobiol Aging. 2004;25(1):5\u201318 (author reply 49-62).","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1074_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jalz.2007.01.019","volume":"3","author":"G Bartzokis","year":"2007","unstructured":"Bartzokis G, Lu PH, Mintz J. Human brain myelination and amyloid beta deposition in Alzheimer\u2019s disease. Alzheimers Dement. 2007;3(2):122\u20135.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1074_CR22","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3390\/ijms19082408","volume":"19","author":"P LoPresti","year":"2018","unstructured":"LoPresti P. Tau in Oligodendrocytes Takes Neurons in Sickness and in Health. Int J Mol Sci. 2018;19(8):2408.","journal-title":"Int J Mol Sci."},{"issue":"6376","key":"1074_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1126\/science.aan4183","volume":"359","author":"L Cantuti-Castelvetri","year":"2018","unstructured":"Cantuti-Castelvetri L, Fitzner D, Bosch-Queralt M, Weil MT, Su M, Sen P, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 2018;359(6376):684\u20138.","journal-title":"Science"},{"issue":"7","key":"1074_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.neuron.2021.01.027","volume":"109","author":"S Safaiyan","year":"2021","unstructured":"Safaiyan S, Besson-Girard S, Kaya T, Cantuti-Castelvetri L, Liu L, Ji H, et al. White matter aging drives microglial diversity. Neuron. 2021;109(7):1100-17 e10.","journal-title":"Neuron."},{"key":"1074_CR25","doi-asserted-by":"crossref","unstructured":"Depp C, Sun T, Sasmita AO, Spieth L, Berghoff SA, Steixner-Kumar AA, et al. Ageing-associated myelin dysfunction drives amyloid deposition in mouse models of Alzheimer\u2019s disease. bioRxiv. 2021:2021.07.31.454562.","DOI":"10.1101\/2021.07.31.454562"},{"issue":"2","key":"1074_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s004010050508","volume":"92","author":"H Braak","year":"1996","unstructured":"Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92(2):197\u2013201.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1074_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/jon.12657","volume":"29","author":"H Liu","year":"2019","unstructured":"Liu H, Rubino C, Dvorak AV, Jarrett M, Ljungberg E, Vavasour IM, et al. Myelin Water Atlas: A Template for Myelin Distribution in the Brain. J Neuroimaging. 2019;29(6):699\u2013706.","journal-title":"J Neuroimaging"},{"issue":"5","key":"1074_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer\u2019s Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement. 2017;13(5):561\u201371.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1074_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/awz026","volume":"142","author":"N Franzmeier","year":"2019","unstructured":"Franzmeier N, Rubinski A, Neitzel J, Kim Y, Damm A, Na DL, et al. Functional connectivity associated with tau levels in ageing, Alzheimer\u2019s, and small vessel disease. Brain. 2019;142(4):1093\u2013107.","journal-title":"Brain"},{"issue":"4","key":"1074_CR30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578\u201386.","journal-title":"Ann Neurol"},{"issue":"3","key":"1074_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe VJ, Lundt ES, Albertson SM, Min H-K, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561\u201371.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1074_CR32","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid \u03b2-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography. JAMA Neurol. 2014;71(10):1282\u20139.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1074_CR33","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000004887","volume":"90","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Smith R, Strandberg O, Palmqvist S, Scholl M, Insel PS, et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology. 2018;90(5):e388\u201395.","journal-title":"Neurology"},{"issue":"7","key":"1074_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","volume":"11","author":"WJ Jagust","year":"2015","unstructured":"Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The ADNI PET Core: 2015. Alzheimer\u2019s Dementia. 2015;11(7):757\u201371.","journal-title":"Alzheimer's Dementia"},{"issue":"3","key":"1074_CR35","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.neuroimage.2010.09.025","volume":"54","author":"BB Avants","year":"2011","unstructured":"Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54(3):2033\u201344.","journal-title":"Neuroimage"},{"issue":"9","key":"1074_CR36","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1093\/cercor\/bhx179","volume":"28","author":"A Schaefer","year":"2018","unstructured":"Schaefer A, Kong R, Gordon EM, Laumann TO, Zuo XN, Holmes AJ, et al. Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic Functional Connectivity MRI. Cereb Cortex. 2018;28(9):3095\u2013114.","journal-title":"Cereb Cortex"},{"key":"1074_CR37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. Neuroimage. 2017;157:448\u201363.","journal-title":"Neuroimage"},{"key":"1074_CR38","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.dib.2017.10.024","volume":"15","author":"SL Baker","year":"2017","unstructured":"Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief. 2017;15:648\u201357.","journal-title":"Data Brief"},{"issue":"Pt 9","key":"1074_CR39","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/brain\/aww163","volume":"139","author":"R Smith","year":"2016","unstructured":"Smith R, Puschmann A, Scholl M, Ohlsson T, van Swieten J, Honer M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139(Pt 9):2372\u20139.","journal-title":"Brain"},{"key":"1074_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuroimage.2013.04.127","volume":"80","author":"MF Glasser","year":"2013","unstructured":"Glasser MF, Sotiropoulos SN, Wilson JA, Coalson TS, Fischl B, Andersson JL, et al. The minimal preprocessing pipelines for the Human Connectome Project. Neuroimage. 2013;80:105\u201324.","journal-title":"Neuroimage"},{"issue":"9","key":"1074_CR41","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1093\/cercor\/bhy152","volume":"28","author":"H Braak","year":"2018","unstructured":"Braak H, Del Tredici K. Spreading of Tau Pathology in Sporadic Alzheimer\u2019s Disease Along Cortico-cortical Top-Down Connections. Cereb Cortex. 2018;28(9):3372\u201384.","journal-title":"Cereb Cortex"},{"issue":"5","key":"1074_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27(5):871\u201381.","journal-title":"Nat Med"},{"issue":"6","key":"1074_CR43","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.neuron.2011.12.040","volume":"73","author":"A Raj","year":"2012","unstructured":"Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73(6):1204\u201315.","journal-title":"Neuron"},{"issue":"8","key":"1074_CR44","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.neurobiolaging.2009.08.007","volume":"32","author":"G Bartzokis","year":"2011","unstructured":"Bartzokis G. Alzheimer\u2019s disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging. 2011;32(8):1341\u201371.","journal-title":"Neurobiol Aging"},{"issue":"14","key":"1074_CR45","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.neuron.2021.05.012","volume":"109","author":"JF Chen","year":"2021","unstructured":"Chen JF, Liu K, Hu B, Li RR, Xin W, Chen H, et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer\u2019s disease. Neuron. 2021;109(14):2292-307 e5.","journal-title":"Neuron"},{"issue":"1","key":"1074_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaneurol.2016.3232","volume":"74","author":"DC Dean 3rd","year":"2017","unstructured":"Dean DC 3rd, Hurley SA, Kecskemeti SR, O\u2019Grady JP, Canda C, Davenport-Sis NJ, et al. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurol. 2017;74(1):41\u20139.","journal-title":"JAMA Neurol"},{"key":"1074_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neurobiolaging.2017.10.017","volume":"62","author":"M Bulk","year":"2018","unstructured":"Bulk M, Abdelmoula WM, Nabuurs RJA, van der Graaf LM, Mulders CWH, Mulder AA, et al. Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer\u2019s disease. Neurobiol Aging. 2018;62:231\u201342.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"1074_CR48","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00401-010-0657-2","volume":"119","author":"S Mitew","year":"2010","unstructured":"Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC. Focal demyelination in Alzheimer\u2019s disease and transgenic mouse models. Acta Neuropathol. 2010;119(5):567\u201377.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1074_CR49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6(1):22.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"1074_CR50","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","volume":"182","author":"WT Chen","year":"2020","unstructured":"Chen WT, Lu A, Craessaerts K, Pavie B, Sala Frigerio C, Corthout N, et al. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer\u2019s Disease. Cell. 2020;182(4):976-91 e19.","journal-title":"Cell"},{"key":"1074_CR51","doi-asserted-by":"crossref","unstructured":"Brase L, You S-F, del Aguila J, Dai Y, Novotny BC, Soriano-Tarraga C, et al. A landscape of the genetic and cellular heterogeneity in Alzheimer disease. medRxiv. 2021:2021.11.30.21267072.","DOI":"10.1101\/2021.11.30.21267072"},{"issue":"53","key":"1074_CR52","doi-asserted-by":"publisher","first-page":"55833","DOI":"10.1074\/jbc.M409954200","volume":"279","author":"A Schneider","year":"2004","unstructured":"Schneider A, Araujo GW, Trajkovic K, Herrmann MM, Merkler D, Mandelkow EM, et al. Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J Biol Chem. 2004;279(53):55833\u20139.","journal-title":"J Biol Chem"},{"issue":"41","key":"1074_CR53","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1523\/JNEUROSCI.2691-05.2005","volume":"25","author":"M Higuchi","year":"2005","unstructured":"Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ, Lee VM. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci. 2005;25(41):9434\u201343.","journal-title":"J Neurosci"},{"key":"1074_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neurobiolaging.2016.03.027","volume":"43","author":"TA Couttas","year":"2016","unstructured":"Couttas TA, Kain N, Suchowerska AK, Quek LE, Turner N, Fath T, et al. Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer\u2019s disease. Neurobiol Aging. 2016;43:89\u2013100.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"1074_CR55","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1523\/JNEUROSCI.22-03-00698.2002","volume":"22","author":"C Klein","year":"2002","unstructured":"Klein C, Kr\u00e4mer E-M, Cardine A-M, Schraven B, Brandt R, Trotter J. Process Outgrowth of Oligodendrocytes Is Promoted by Interaction of Fyn Kinase with the Cytoskeletal Protein Tau. J Neurosci. 2002;22(3):698.","journal-title":"J Neurosci"},{"issue":"5","key":"1074_CR56","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jnr.21196","volume":"85","author":"C Seiwa","year":"2007","unstructured":"Seiwa C, Yamamoto M, Tanaka K, Fukutake M, Ueki T, Takeda S, et al. Restoration of FcRgamma\/Fyn signaling repairs central nervous system demyelination. J Neurosci Res. 2007;85(5):954\u201366.","journal-title":"J Neurosci Res"},{"issue":"7","key":"1074_CR57","doi-asserted-by":"publisher","first-page":"108045","DOI":"10.1016\/j.celrep.2020.108045","volume":"32","author":"A Briner","year":"2020","unstructured":"Briner A, Gotz J, Polanco JC. Fyn Kinase Controls Tau Aggregation In Vivo. Cell Rep. 2020;32(7):108045.","journal-title":"Cell Rep"},{"issue":"8","key":"1074_CR58","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/nn.4325","volume":"19","author":"S Safaiyan","year":"2016","unstructured":"Safaiyan S, Kannaiyan N, Snaidero N, Brioschi S, Biber K, Yona S, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat Neurosci. 2016;19(8):995\u20138.","journal-title":"Nat Neurosci"},{"issue":"7784","key":"1074_CR59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669\u201373.","journal-title":"Nature"},{"issue":"1","key":"1074_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6(1):22.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"1074_CR61","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"1","key":"1074_CR62","doi-asserted-by":"crossref","first-page":"e12242","DOI":"10.1002\/trc2.12242","volume":"8","author":"J Fessel","year":"2022","unstructured":"Fessel J. Reversing Alzheimer\u2019s disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy. Alzheimers Dement (N Y). 2022;8(1):e12242.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7555","key":"1074_CR63","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature14335","volume":"522","author":"FJ Najm","year":"2015","unstructured":"Najm FJ, Madhavan M, Zaremba A, Shick E, Karl RT, Factor DC, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015;522(7555):216\u201320.","journal-title":"Nature"},{"issue":"6","key":"1074_CR64","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrd4641","volume":"14","author":"M Cully","year":"2015","unstructured":"Cully M. Neurodegenerative diseases: Repurposing for remyelination. Nat Rev Drug Discov. 2015;14(6):383.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1074_CR65","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nm.3618","volume":"20","author":"F Mei","year":"2014","unstructured":"Mei F, Fancy SPJ, Shen YA, Niu J, Zhao C, Presley B, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20(8):954\u201360.","journal-title":"Nat Med"},{"key":"1074_CR66","doi-asserted-by":"publisher","first-page":"e18246","DOI":"10.7554\/eLife.18246","volume":"5","author":"F Mei","year":"2016","unstructured":"Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, Lorrain DS, et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016;5:e18246.","journal-title":"Elife"},{"issue":"10111","key":"1074_CR67","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","volume":"390","author":"AJ Green","year":"2017","unstructured":"Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481\u20139.","journal-title":"Lancet"},{"key":"1074_CR68","doi-asserted-by":"publisher","first-page":"733945","DOI":"10.3389\/fcell.2021.733945","volume":"9","author":"YY Xie","year":"2021","unstructured":"Xie YY, Pan TT, Xu DE, Huang X, Tang Y, Huang W, et al. Clemastine Ameliorates Myelin Deficits via Preventing Senescence of Oligodendrocytes Precursor Cells in Alzheimer\u2019s Disease Model Mouse. Front Cell Dev Biol. 2021;9:733945.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1074_CR69","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tins.2019.03.009","volume":"42","author":"HE Moller","year":"2019","unstructured":"Moller HE, Bossoni L, Connor JR, Crichton RR, Does MD, Ward RJ, et al. Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. Trends Neurosci. 2019;42(6):384\u2013401.","journal-title":"Trends Neurosci"},{"issue":"4","key":"1074_CR70","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.neuroimage.2007.12.008","volume":"40","author":"C Laule","year":"2008","unstructured":"Laule C, Kozlowski P, Leung E, Li DK, Mackay AL, Moore GR. Myelin water imaging of multiple sclerosis at 7 T: correlations with histopathology. Neuroimage. 2008;40(4):1575\u201380.","journal-title":"Neuroimage"},{"issue":"6","key":"1074_CR71","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/1352458506070928","volume":"12","author":"C Laule","year":"2006","unstructured":"Laule C, Leung E, Lis DK, Traboulsee AL, Paty DW, MacKay AL, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler. 2006;12(6):747\u201353.","journal-title":"Mult Scler"},{"key":"1074_CR72","doi-asserted-by":"publisher","first-page":"e61523","DOI":"10.7554\/eLife.61523","volume":"9","author":"M Mancini","year":"2020","unstructured":"Mancini M, Karakuzu A, Cohen-Adad J, Cercignani M, Nichols TE, Stikov N. An interactive meta-analysis of MRI biomarkers of myelin. Elife. 2020;9:e61523.","journal-title":"Elife"},{"issue":"5","key":"1074_CR73","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/jmri.26707","volume":"50","author":"E Papadaki","year":"2019","unstructured":"Papadaki E, Kavroulakis E, Kalaitzakis G, Karageorgou D, Makrakis D, Maris TG, et al. Age-related deep white matter changes in myelin and water content: A T(2) relaxometry study. J Magn Reson Imaging. 2019;50(5):1393\u2013404.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"1074_CR74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JAD-201134","volume":"80","author":"E Dao","year":"2021","unstructured":"Dao E, Tam R, Hsiung GR, Ten Brinke L, Crockett R, Barha CK, et al. Exploring the Contribution of Myelin Content in Normal Appearing White Matter to Cognitive Outcomes in Cerebral Small Vessel Disease. J Alzheimers Dis. 2021;80(1):91\u2013101.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1074_CR75","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jmri.25849","volume":"47","author":"E Kavroulakis","year":"2018","unstructured":"Kavroulakis E, Simos PG, Kalaitzakis G, Maris TG, Karageorgou D, Zaganas I, et al. Myelin content changes in probable Alzheimer\u2019s disease and mild cognitive impairment: Associations with age and severity of neuropsychiatric impairment. J Magn Reson Imaging. 2018;47(5):1359\u201372.","journal-title":"J Magn Reson Imaging"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01074-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T12:23:47Z","timestamp":1701087827000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01074-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.02.22271746","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For ADNI, ethical approval was obtained by the ADNI investigators; all study participants provided written informed consent.For BioFINDER-1, ethical approval was given by the ethics committee of Lund University, Sweden. Imaging procedures were approved by the Swedish Medical Product Agency and the Radiation Safety Committee at Sk\u00e5ne University Hospital, Sweden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.E and N.F. receive research funding from Eli Lilly; M.E. serves as a consultant for Eli Lilly. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}